Middle East And Africa Gastric Cancer Diagnostics Market
Tamanho do mercado em biliões de dólares
CAGR :
% 
 Período de previsão |
2024 –2030 |
 Tamanho do mercado (ano base ) | |
 Tamanho do mercado ( Ano de previsão) | USD 69.63 |
 CAGR |
% |
| Principais participantes do mercado |
>Mercado de diagnóstico de cancro gástrico no Médio Oriente e África, por tipo de produto (instrumentos, reagentes e consumíveis, serviços), tipo de diagnóstico (teste confirmatório, testes de rastreio de cancro gástrico/exame físico), grupo etário (adulto, pediátrico e geriatria), tipo de doença (Adenocarcinoma intestinal ou difuso, tumor carcinoide, tumor estromal gastrointestinal (GIST), linfoma gástrico e outras), estádio (estádio 0, estádio I, estádio II, estádio III), género (masculino e feminino) , tipo de amostra (sangue, tecido , urina e fezes), utilizadores finais (laboratórios de diagnóstico, hospitais, institutos de investigação do cancro, clínicas especializadas em oncologia e outros), canal de distribuição (concursos directos e vendas a retalho) - tendências e previsões do setor para 2030.
Análise e insights de mercado de diagnóstico de cancro gástrico no Médio Oriente e África
O aumento da população geriátrica no Médio Oriente e em África está a impulsionar o crescimento da indústria de diagnóstico do cancro gástrico. A prevalência de tumores gastrointestinais e linfomas também alimentou a procura por diagnósticos de cancro gástrico. A principal restrição do mercado é a necessidade de baixar os elevados preços associados aos testes de diagnóstico do cancro, para que mesmo os países em desenvolvimento possam beneficiar dos mesmos.
Um grande número de participantes no mercado estão a oferecer produtos de diagnóstico do cancro gástrico com inovações que abrem caminho para o crescimento do mercado de diagnóstico do cancro gástrico no Médio Oriente e em África.
A Data Bridge Market Research analisa que o mercado de diagnóstico do cancro gástrico no Médio Oriente e em África deverá atingir o valor de 69,63 milhões de dólares até 2030, com um CAGR de 7,4% durante o período de previsão. Os reagentes e consumíveis representam o maior segmento de tipos de produtos no mercado devido à crescente procura de kits e reagentes, e o aumento dos gastos em saúde acelerou a procura de dispositivos médicos inteligentes.
|
Métrica de relatório |
Detalhes |
|
Período de previsão |
2023 a 2030 |
|
Ano base |
2022 |
|
Anos históricos |
2021 (personalizável para 2015-2020) |
|
Unidades Quantitativas |
Receita em milhões de dólares, volumes em unidades, preços em dólares |
|
Segmentos cobertos |
Por tipo de produto (instrumentos, reagentes e consumíveis, serviços), tipo de diagnóstico (teste confirmatório, testes de rastreio do cancro gástrico/exame físico), grupo etário (adulto, pediátrico e geriátrico), tipo de doença (adenocarcinoma intestinal ou difuso , tumor carcinoide, Tumor estromal gastrointestinal (GIST), linfoma gástrico e outros), estádio (estádio 0, estádio I, estádio II, estádio III), género (masculino e feminino), tipo de amostra (sangue, tecido, urina e fezes ), utilizadores finais (Laboratórios de Diagnóstico, Hospitais, Institutos de Investigação do Cancro, Clínicas de Especialidade Oncológica e Outros), Canal de Distribuição (Concursos Directos e Vendas a Retalho) |
|
Países abrangidos |
Arábia Saudita, África do Sul, Emirados Árabes Unidos, Israel, Egito e resto do Médio Oriente e África |
|
Participantes do mercado abrangidos |
BIOMÉRIEUX, Myriad Genetics, Inc., Vela Diagnostics, Abbott, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, General Electric, Agilent Technologies, Inc., Biohit Oyj, DiaSorin SpA, Paragon Genomics, Inc., e QIAGEN entre outros |
Definição de mercado
O cancro do estômago é um tipo de cancro que começa no estômago e que se espalha por todo o corpo. O estômago é uma bolsa muscular situada imediatamente abaixo das costelas, na parte superior do abdómen. O estômago absorve e retém os alimentos que ingerimos antes de os quebrar e digerir. O cancro do estômago, vulgarmente designado por cancro gástrico, pode ocorrer em qualquer secção do estômago. O cancro do estômago desenvolve-se na maior parte do estômago na maior parte do mundo (corpo do estômago). Vários testes de diagnóstico utilizados para o diagnóstico de cancro incluem testes de pré-triagem, biópsia, biomarcadores, exames de imagem, PET/CT e ecografia, entre outros.
O cancro é causado pela proliferação celular anormal e descontrolada que tem a capacidade de se espalhar e invadir outras partes do corpo. As alterações no gene fazem com que uma única célula ou algumas células se expandam e se repliquem, que é quando o cancro começa. Isto pode levar ao crescimento de um tumor, que é uma massa anormal de tecido. A criação de células cancerígenas no revestimento do estômago é conhecida como cancro gástrico ou cancro do estômago. A dieta e os distúrbios estomacais são fatores de risco para o cancro gástrico.
Dinâmica do mercado de diagnóstico do cancro gástrico no Médio Oriente e África
Esta secção trata da compreensão dos impulsionadores do mercado, vantagens, oportunidades, restrições e desafios. Tudo isto é discutido em detalhe abaixo:
Motoristas
- Aumento da incidência de tumores gastrointestinais, linfoma e adenocarcinoma
De acordo com um relatório publicado na Clinical Medicine, o cancro gástrico é o quinto cancro mais comum e a quarta principal causa de morte por cancro em todo o mundo em 2020. Em 2020, cerca de 1,1 milhões de casos (720.000 homens e 370.000 mulheres) de cancro gástrico foram diagnosticados em todo o mundo. O cancro gástrico é responsável por cerca de 1 em cada 12 mortes oncológicas. Todos os anos são diagnosticados cerca de um milhão de novos casos de cancro do estômago em todo o mundo.
Prevê-se que a incidência do cancro gástrico aumente, devido ao envelhecimento e ao aumento da população, do estilo de vida e das alterações socioeconómicas. Variações acentuadas na raça, nas normas socioculturais, nos comportamentos e nas tendências alimentares reflectem-se no fardo e na distribuição do cancro nas diferentes regiões do mundo.
Assim, prevê-se que a crescente incidência de cancros em todo o mundo acelere a procura de diagnósticos de cancro gástrico. Assim, prevê-se que o aumento das taxas de incidência de tumores gastrointestinais, linfoma e adenocarcinoma impulsione o crescimento do mercado de diagnóstico do cancro gástrico no Médio Oriente e em África.
- Aumento do consumo de álcool e aumento do tabagismo
Epidemiological, clinical, and laboratory evidence point to a behavioral relationship between cigarette smoking and alcohol consumption. The combined use of cigarettes and alcohol poses health concerns in addition to those posed by smoking alone and so represents a severe public health issue that warrants further investigation.
A chemical chain reaction occurs every time a smoker inhales a lit cigarette, producing dozens of hazardous chemicals. Cigarette smoke contains substances that are inhaled through the lips, through the tongue and mouth, down the throat, and into the lungs, producing inflammation and exposing those bodily parts to cancer-causing chemicals.
Thus, the rise in alcohol consumption and surge in smoking is expected to drive the Middle East and Africa gastric cancer market growth.
Opportunity
-
Rise in adoption of automated systems
Cancer is a system and network illness. This indicates that in a cancer cell, certain network-related genes stop working properly. Complex interactions in such gene networks should be addressed in cancer treatment. Artificial intelligence (AI) algorithms, in particular, have been rapidly evolving, which is reflected in oncology's progress.
Machine learning and neural networks are becoming increasingly significant in precision oncology and system medicine. The combination of imaging data with clinical and molecular data opens up a world of possibilities. Radiogenomics, for instance, is a new field focused on multidimensional data processing. It can also benefit from AI advancements.
Thus, the increased adoption of automated systems acts as an opportunity for the growth of this market.
Restraint/Challenge
- Lack of sufficient financial support from health insurance policies
To achieve their objectives, health systems require financial resources. Human resources, hospital care, and medications are the most expensive aspects of most healthcare systems. In most tropical countries, health care is funded through a combination of government, private (mainly out-of-pocket) spending, and international help.
Healthcare finance remains a key concern for low- and lower-middle-income countries. Many upper-middle-income countries in Latin America, Africa, and Asia have been able to establish health finance arrangements that cover large segments of their populations. These measures enable access to health care while also protecting individuals from catastrophic debt incurred as a result of that access. Finance, on the other hand, is a major obstacle to health care delivery in low-income countries (the bulk of which are in Sub-Saharan Africa).
Thus, the lack of sufficient financial support from health insurance policies acts as a restraint to market's growth.
Recent Developments
- Em outubro de 2022, a General Electric Company colaborou com vários institutos de investigação, como os hospitais da Universidade de Cambridge, a Sophia Genetics e, anteriormente, com a Optellum para utilizar dados de imagem em colaboração com a inteligência artificial. Isto ajudará a reduzir o tempo de diagnóstico de vários tipos de cancro e a prestar cuidados personalizados aos pacientes. Isto ajudou a empresa a alargar os seus horizontes no diagnóstico de cancro
- Em março de 2020, a Thermo Fisher Scientific Inc. anunciou que iria adquirir a QIAGEN, uma empresa de diagnóstico molecular e saúde com sede na Holanda. Esta aquisição por parte da empresa irá aumentar o seu portfólio de produtos no mercado, levando ao aumento de receitas no futuro
Âmbito do mercado de diagnóstico de cancro gástrico no Médio Oriente e África
O mercado de diagnóstico do cancro gástrico do Médio Oriente e África está segmentado em nove segmentos notáveis com base no tipo de produto, tipo de diagnóstico, faixa etária, tipo de doença, estádio, género, amostra, utilizador final e canal de distribuição. O crescimento entre segmentos ajuda-o a analisar os nichos de crescimento e as estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.
TIPO DE PRODUTO
- Instrumentos
- Reagentes e consumíveis
- Serviços
Com base no tipo de produto, o mercado está segmentado em instrumentos, reagentes e consumíveis e serviços.
TIPO DE DIAGNÓSTICO
- Teste Confirmatório
- Testes de rastreio de cancro gástrico/exame físico
Com base no tipo de diagnóstico, o mercado está segmentado em testes de rastreio do cancro gástrico/exame físico e testes confirmatórios.
FAIXA ETÁRIA
- Adulto
- Pediátrico
- Geriatria
Com base na faixa etária, o mercado está segmentado em adulto, pediátrico e geriatria.
TIPO
- Adenocarcinoma intestinal ou difuso
- Tumor Carcinóide
- Tumor estromal gastrointestinal (GIST)
- Linfoma Gástrico
- Outros
Com base no tipo, o mercado está segmentado em adenocarcinoma intestinal ou difuso, tumor carcinoide, tumor estromal gastrointestinal (GIST), linfoma gástrico, entre outros.
FASE
- Estágio 0
- Estágio I
- Estágio II
- Estágio III
Com base no estágio, o mercado está segmentado em estágio 0, estágio I, estágio II e estágio III.
GÉNERO
- Macho
- Fêmea
Com base no género, o mercado está segmentado em masculino e feminino.
TIPO DE AMOSTRA
- Sangue
- Lenço
- Urina
- Banco
Com base no tipo de amostra, o mercado está segmentado em sangue, tecido, urina e fezes.
UTILIZADOR FINAL
- Laboratórios de Diagnóstico
- Hospitais
- Institutos de Investigação do Cancro
- Clínicas Especializadas em Oncologia
- Outros
Com base nos utilizadores finais, o mercado está segmentado em laboratórios de diagnóstico, hospitais, institutos de investigação do cancro, clínicas especializadas em oncologia, entre outros.
CANAL DE DISTRIBUIÇÃO
- Licitações Diretas
- Vendas no Retalho
Com base no canal de distribuição, o mercado está segmentado em concurso direto e vendas a retalho.
Análise/perspetivas regionais do mercado de diagnóstico do cancro gástrico no Médio Oriente e África
O mercado de diagnóstico do cancro gástrico do Médio Oriente e África está segmentado em nove segmentos notáveis com base no tipo de produto, tipo de diagnóstico, faixa etária, tipo de doença, estádio, género, amostra, utilizador final e canal de distribuição.
Os países abordados neste relatório de mercado são a África do Sul, Arábia Saudita, Emirados Árabes Unidos, Egito, Israel e o resto do Médio Oriente e África.
Em 2023, prevê-se que a África do Sul domine devido ao aumento da necessidade de uma comunicação de saúde eficiente e ágil.
A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado interno que impactam as tendências atuais e futuras do mercado. Dados como novas vendas, vendas de reposição, demografia do país, atos regulamentares e tarifas de importação e exportação são alguns dos principais indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas do Médio Oriente e de África e os desafios enfrentados devido à concorrência grande ou escassa de marcas locais e nacionais, e o impacto dos canais de vendas, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.
Análise do cenário competitivo e da quota de mercado do diagnóstico do cancro gástrico
O panorama competitivo do mercado de diagnóstico do cancro gástrico no Médio Oriente e em África fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em I&D, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, aprovações de produtos, largura e amplitude do produto, domínio de aplicação, tipo de produto linha de vida curva. Os dados fornecidos acima estão apenas relacionados com o foco da empresa no mercado de diagnóstico do cancro gástrico.
Alguns dos principais players que operam no mercado de diagnóstico do cancro gástrico do Médio Oriente e África são a BIOMÉRIEUX, Myriad Genetics, Inc., Vela Diagnostics, Abbott, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, General Electric, Agilent Technologies, Inc., Biohit Oyj, DiaSorin SpA, Paragon Genomics, Inc. e QIAGEN, entre outros.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PESTEL'S MODEL
4.2 PORTER'S 5 FORCES
4.3 EPIDEMIOLOGY
4.4 BRAND ANALYSIS
4.5 ROLE OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING (ML): MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET
4.6 INDUSTRY INSIGHTS:
5 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, REGULATORY
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASE IN INCIDENCE OF GASTROINTESTINAL TUMOURS, LYMPHOMA, AND ADENOCARCINOMA
6.1.2 RISE IN ALCOHOL CONSUMPTION AND SURGE IN SMOKING
6.1.3 INCREASE IN THE GERIATRIC POPULATION
6.1.4 RECENT ADVANCEMENTS IN GASTRIC CANCER DIAGNOSTICS PRODUCTS
6.2 RESTRAINTS
6.2.1 HIGH COST OF GASTRIC CANCER DIAGNOSTIC TEST
6.2.2 LACK OF SUFFICIENT FINANCIAL SUPPORT FROM HEALTH INSURANCE POLICIES
6.3 OPPORTUNITIES
6.3.1 RISE IN THE ADOPTION OF AUTOMATED SYSTEMS
6.3.2 INCREASED RESEARCH AND DEVELOPMENT ON CANCER DIAGNOSTICS PRODUCTS
6.3.3 STRATEGIC INITIATIVES BY EMERGING PLAYERS
6.4 CHALLENGES
6.4.1 STRINGENT REGULATIONS AND POLICIES FOR APPROVING THE COMPLICATED NATURE OF RADIATION DEVICES
6.4.2 LIMITATIONS OF RADIATION TESTS
7 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 REAGENTS & CONSUMABLES
7.2.1 KITS
7.2.1.1 DNA POLYMERASE KITS
7.2.1.2 PCR KITS
7.2.1.3 NUCLEIC ACID ISOLATION KITS
7.2.1.4 OTHERS
7.2.2 REAGENTS
7.2.2.1 ASSAYS
7.2.2.2 BUFFERS
7.2.2.3 PRIMERS
7.2.2.4 OTHERS
7.3 INSTRUMENTS
7.4 SERVICES
8 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE
8.1 OVERVIEW
8.2 CONFIRMATORY TEST
8.2.1 IMAGING TESTS
8.2.1.1 PET SCAN/CT SCAN
8.2.1.2 CT SCAN
8.2.1.3 ULTRASOUND
8.2.1.4 MRI
8.2.1.5 X-RAY
8.2.2 BIOMARKER
8.2.2.1 DNA BIOMARKER
8.2.2.2 RNA BIOMARKER
8.2.2.3 PROTEIN BIOMARKER
8.2.3 BIOPSY
8.3 GASTRIC CANCER SCREENING TESTS/PHYSICAL EXAM
9 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP
9.1 OVERVIEW
9.2 GERIATRICS
9.3 ADULT
9.4 PEDIATRIC
10 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE
10.1 OVERVIEW
10.2 INTESTINAL OR DIFFUSE ADENOCARCINOMA
10.3 CARCINOID TUMOR
10.4 GASTROINTESTINAL STROMAL TUMOR
10.5 GASTRIC LYMPHOMA
10.6 OTHERS
11 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE
11.1 OVERVIEW
11.2 STAGE I
11.2.1 STAGE IA
11.2.2 STAGE IB
11.3 STAGE II
11.3.1 STAGE IIA
11.3.2 STAGE IIB
11.4 STAGE III
11.4.1 STAGE IIIA
11.4.2 STAGE IIIB
11.4.3 STAGE IIIC
11.5 STAGE 0
12 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER
12.1 OVERVIEW
12.2 MALE
12.3 FEMALE
13 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE
13.1 OVERVIEW
13.2 STOOL
13.3 TISSUE
13.4 BLOOD
13.5 URINE
14 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 DIAGNOSTIC LABORATORIES
14.4 CANCER RESEARCH INSTITUTES
14.5 ONCOLOGY SPECIALTY CLINICS
14.6 OTHERS
15 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDERS
15.3 RETAIL SALES
16 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION
16.1 MIDDLE EAST AND AFRICA
16.1.1 SOUTH AFRICA
16.1.2 SAUDI ARABIA
16.1.3 U.A.E
16.1.4 EGYPT
16.1.5 ISRAEL
16.1.6 REST OF MIDDLE EAST AND AFRICA
17 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 F. HOFFMANN-LA ROCHE LTD
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENT
19.2 GENERAL ELECTRIC
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENT
19.3 ABBOTT
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 QIAGEN
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENT
19.5 MYRIAD GENETICS, INC.
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENT
19.6 ACON LABORATORIES, INC.
19.6.1 COMPANY SNAPSHOT
19.6.2 PRODUCT PORTFOLIO
19.6.3 RECENT DEVELOPMENT
19.7 ADVACARE PHARMA
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENT
19.8 AGILENT TECHNOLOGIES, INC.
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 BIOMÉRIEUX
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENT
19.1 BIOCEPT, INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENT
19.11 BIOHIT OYJ
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENT
19.12 DIASORIN S.P.A
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENT
19.13 ENDOFOTONICS PTE LTD
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENT
19.14 FOUNDATION MEDICINE, INC.
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENTS
19.15 FUJIREBIO (AN H.U. GROUP COMPANY)
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENT
19.16 MIRXES PTE LTD.
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENT
19.17 PARAGON GENOMICS, INC.
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENTS
19.18 TECO DIAGNOSTICS
19.18.1 COMPANY SNAPSHOT
19.18.2 PRODUCT PORTFOLIO
19.18.3 RECENT DEVELOPMENT
19.19 THERMO FISHER SCIENTIFIC INC.
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUE ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENTS
19.2 VELA DIAGNOSTICS
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
Lista de Tabela
TABLE 1 APPROVED COMPANION DIAGNOSTIC DEVICE
TABLE 2 THE BELOW-MENTIONED LIST SHOWS THE COST OF PET SCAN FOR CANCER DIAGNOSIS IN DIFFERENT REGIONS ACROSS THE GLOBE-
TABLE 3 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA REAGENT AND CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA INSTRUMENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA SERVICES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA CONFIRMATORY TEST IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA CONFIRMATORY TEST IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA GASTRIC CANCER SCREENING TESTS/PHYSICAL EXAM IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA GERIATRICS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA ADULT IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA PEDIATRIC IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA INTESTINAL OR DIFFUSE ADENOCARCINOMA IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA CARCINOID TUMOR IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA GASTROINTESTINAL STROMAL TUMOR IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA GASTRIC LYMPHOMA IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA OTHERS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA STAGE 0 IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA MALE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA FEMALE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 38 MIDDLE EAST & AFRICA STOOL IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA TISSUE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA BLOOD IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA URINE IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA HOSPITALS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA DIAGNOSTIC LABORATORIES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA CANCER RESEARCH INSTITUTES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA ONCOLOGY SPECIALTY CLINICS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA OTHERS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA DIRECT TENDERS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA RETAIL SALES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 58 MIDDLE EAST & AFRICA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 59 MIDDLE EAST & AFRICA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 60 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 61 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 62 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 63 MIDDLE EAST & AFRICA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 64 MIDDLE EAST & AFRICA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 65 MIDDLE EAST & AFRICA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 66 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 67 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 68 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 69 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 70 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 71 SOUTH AFRICA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 72 SOUTH AFRICA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 73 SOUTH AFRICA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 74 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 75 SOUTH AFRICA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 76 SOUTH AFRICA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 77 SOUTH AFRICA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 78 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 79 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 80 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 81 SOUTH AFRICA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 82 SOUTH AFRICA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 83 SOUTH AFRICA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 84 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 85 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 86 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 87 SOUTH AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 88 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 89 SAUDI ARABIA REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 90 SAUDI ARABIA KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 91 SAUDI ARABIA REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 92 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 93 SAUDI ARABIA CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 94 SAUDI ARABIA IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 95 SAUDI ARABIA BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 96 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 97 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 98 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 99 SAUDI ARABIA STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 100 SAUDI ARABIA STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 101 SAUDI ARABIA STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 102 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 103 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 104 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 105 SAUDI ARABIA GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 106 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 107 U.A.E REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 108 U.A.E KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 109 U.A.E REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 110 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 111 U.A.E CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 112 U.A.E IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 113 U.A.E BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 114 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 115 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 116 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 117 U.A.E STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 118 U.A.E STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 119 U.A.E STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 120 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 121 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 122 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 123 U.A.E GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 124 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 125 EGYPT REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 126 EGYPT KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 127 EGYPT REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 128 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 129 EGYPT CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 130 EGYPT IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 131 EGYPT BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 132 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 133 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 134 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 135 EGYPT STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 136 EGYPT STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 137 EGYPT STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 138 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 139 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 140 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 141 EGYPT GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 142 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 143 ISRAEL REAGENTS & CONSUMABLES IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 144 ISRAEL KITS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 145 ISRAEL REAGENTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 146 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 147 ISRAEL CONFIRMATORY TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 148 ISRAEL IMAGING TESTS IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 149 ISRAEL BIOMARKER IN GASTRIC CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE, 2021-2030 (USD MILLION)
TABLE 150 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 151 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY DISEASE TYPE, 2021-2030 (USD MILLION)
TABLE 152 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 153 ISRAEL STAGE I IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 154 ISRAEL STAGE II IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 155 ISRAEL STAGE III IN GASTRIC CANCER DIAGNOSTICS MARKET, BY STAGE, 2021-2030 (USD MILLION)
TABLE 156 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 157 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)
TABLE 158 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 159 ISRAEL GASTRIC CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 160 REST OF MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
Lista de Figura
FIGURE 1 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: MIDDLE EAST & AFRICA VS. REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: MARKET END COVERAGE GRID
FIGURE 11 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 12 INCREASE IN THE INCIDENCE OF GASTROINTESTINAL TUMORS, LYMPHOMA, AND ADENOCARCINOMA IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET GROWTH IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 13 REAGENTS AND CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES, OF THE MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET
FIGURE 15 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022
FIGURE 16 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 17 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 18 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 19 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, 2022
FIGURE 20 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, 2023-2030 (USD MILLION)
FIGURE 21 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, CAGR (2023-2030)
FIGURE 22 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE, LIFELINE CURVE
FIGURE 23 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2022
FIGURE 24 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)
FIGURE 25 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030)
FIGURE 26 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 27 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, 2022
FIGURE 28 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, 2023-2030 (USD MILLION)
FIGURE 29 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, CAGR (2023-2030)
FIGURE 30 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 31 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, 2022
FIGURE 32 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, 2023-2030 (USD MILLION)
FIGURE 33 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, CAGR (2023-2030)
FIGURE 34 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY STAGE, LIFELINE CURVE
FIGURE 35 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, 2022
FIGURE 36 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, 2023-2030 (USD MILLION)
FIGURE 37 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, CAGR (2023-2030)
FIGURE 38 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY GENDER, LIFELINE CURVE
FIGURE 39 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, 2022
FIGURE 40 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, 2023-2030 (USD MILLION)
FIGURE 41 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, CAGR (2023-2030)
FIGURE 42 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY SAMPLE TYPE, LIFELINE CURVE
FIGURE 43 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 44 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 45 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 46 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 47 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 48 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 49 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 50 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 51 MIDDLE EAST AND AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 52 MIDDLE EAST AND AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 53 MIDDLE EAST AND AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 54 MIDDLE EAST AND AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 55 MIDDLE EAST AND AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE (2023-2030)
FIGURE 56 MIDDLE EAST & AFRICA GASTRIC CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
